Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: Preliminary results of two pilot trials using paclitaxel and cisplatin

W. Flood, D. J. Lee, A. Trotti, S. Spencer, B. Murphy, F. Khuri, R. DeConti, R. Wheeler, Arlene A. Forastiere

Research output: Contribution to journalArticle


Chemotherapy has been integrated into the initial treatment of patients with locally advanced squamous cell cancer of the head and neck to improve locoregional control and survival. Two strategies for improving these outcomes are the use of new, potentially more effective drugs either with concurrent radiotherapy or as induction regimens. Because of its inherent activity against squamous cell cancer of the head and neck and its radiation- sensitizing properties, paclitaxel may be a valuable agent in the treatment of this patient population. We describe the preliminary results of two trials that evaluated the combination of paclitaxel and cisplatin in patients with locally advanced disease: a phase I trial of weekly paclitaxel and cisplatin with concurrent postoperative radiation therapy in patients with high-risk disease and a phase I/II trial of paclitaxel as a 96-hour infusion in combination with cisplatin as induction therapy. These studies identified tolerable doses of paclitaxel and cisplatin administered in these settings, with apparent clinical activity. These trials formed the basis for subsequent evaluation of induction paclitaxel and cisplatin followed by definitive radiotherapy and concurrent weekly paclitaxel and cisplatin plus radiotherapy.

Original languageEnglish (US)
Pages (from-to)64-69
Number of pages6
JournalSeminars in Radiation Oncology
Issue number2 SUPPL. 1
Publication statusPublished - 1999


ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Cite this